Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.32%
-0.94%
-1.99%
-0.53%
+0.14%
GLUE
Monte Rosa Therapeut
$7.70
Login to see Monte Rosa Therapeut (GLUE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Chart
$4.8 (+60.42%)
$5.16 (+49.22%)
$4.04 (+90.59%)
$5.49 (+40.26%)
GLUE has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
GLUE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
GLUE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
GLUE Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayGLUE Earnings
The TTM reflects 12-month period, providing review of GLUE financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is GLUE current stock price?
What are GLUE stock strengths?
What risks are associated with GLUE stock?
When is GLUE next earnings report?
What is GLUE market cap and volume?
What is GLUE's current Stock IQ?
Should I buy GLUE stock right now?
Is GLUE a Strong Buy right now?
What does a 'Strong Buy' rating mean for GLUE?
What does a 'Strong Sell' rating mean for GLUE?
What factors influence GLUE's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.32%
-0.94%
-1.99%
-0.53%
+0.14%
GLUE
Monte Rosa Therapeut
Current Price
$7.70
Login to unlock Monte Rosa Therapeut (GLUE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$4.8 (+60.42%)
$5.16 (+49.22%)
$4.04 (+90.59%)
$5.49 (+40.26%)
GLUE Analysts Opinion
GLUE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
GLUE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
GLUE Street view is extremely bullish and have negative views on the near-term outlook
GLUE has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
Average key support and resistance price levels.
Login to displayGLUE Earnings
The TTM data reflects the most recent 12-month period, providing overview of GLUE financial performance.
GLUE Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
GLUE Latest Analysis
Monte Rosa Novartis Use AI-Powered Engine To Advance Immune Disease Treatments. ) stock is surging on Monday with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data .Monte Rosa announced a collaboration with ) to develop novel degraders for immune-mediated diseases.Under the terms of the agreement Monte Rosa will receive an upfront payment of $120 million. Monte Rosa will also receive .In total deal value Monte Rosa is eligible to receive up to $5.7 b
Mon Sep 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GLUE Stock trends
GLUE Stock performance
GLUE Stock analysis
GLUE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings